Entropy Technologies LP Lowers Stake in DaVita Inc. (NYSE:DVA)

Entropy Technologies LP lessened its stake in DaVita Inc. (NYSE:DVA) by 13.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,696 shares of the company’s stock after selling 3,609 shares during the period. Entropy Technologies LP’s holdings in DaVita were worth $3,271,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Newbridge Financial Services Group Inc. bought a new position in DaVita in the fourth quarter worth approximately $30,000. Principal Securities Inc. bought a new position in shares of DaVita during the 4th quarter worth $37,000. GAMMA Investing LLC purchased a new position in shares of DaVita during the fourth quarter valued at $60,000. Quest Partners LLC purchased a new position in shares of DaVita during the fourth quarter valued at $74,000. Finally, Quent Capital LLC raised its holdings in shares of DaVita by 21.0% in the first quarter. Quent Capital LLC now owns 581 shares of the company’s stock valued at $80,000 after acquiring an additional 101 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on DVA shares. Truist Financial boosted their price target on shares of DaVita from $135.00 to $150.00 and gave the company a “hold” rating in a report on Wednesday, May 15th. StockNews.com lowered DaVita from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 8th. Finally, Barclays lifted their price target on DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a report on Monday, May 6th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $144.67.

DaVita Stock Up 1.4 %

NYSE DVA traded up $1.96 on Wednesday, hitting $139.68. The stock had a trading volume of 654,101 shares, compared to its average volume of 856,557. The business’s fifty day moving average price is $140.31 and its 200 day moving average price is $129.75. The stock has a market cap of $12.25 billion, a price-to-earnings ratio of 15.87, a price-to-earnings-growth ratio of 1.04 and a beta of 0.87. The company has a debt-to-equity ratio of 7.95, a current ratio of 1.43 and a quick ratio of 1.37. DaVita Inc. has a 52-week low of $71.51 and a 52-week high of $147.93.

DaVita (NYSE:DVA) last announced its earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The company had revenue of $3.07 billion for the quarter, compared to analyst estimates of $3.03 billion. During the same period in the prior year, the company posted $1.58 EPS. The firm’s quarterly revenue was up 6.9% compared to the same quarter last year. Equities research analysts anticipate that DaVita Inc. will post 9.62 earnings per share for the current year.

Insiders Place Their Bets

In other DaVita news, Director Barbara J. Desoer sold 5,030 shares of the firm’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $138.81, for a total value of $698,214.30. Following the completion of the transaction, the director now owns 10,954 shares of the company’s stock, valued at $1,520,524.74. The transaction was disclosed in a filing with the SEC, which is available at this link. 2.00% of the stock is owned by insiders.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.